Genetech Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 02-12-2024
- Paid Up Capital ₹ 0.10 M
as on 02-12-2024
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
as on 02-12-2024
- Revenue 11.51%
(FY 2022)
- Profit 23.22%
(FY 2022)
- Ebitda -126.32%
(FY 2022)
- Net Worth 1.72%
(FY 2022)
- Total Assets 15.66%
(FY 2022)
About Genetech Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Meena Aggarwal and Ashish Aggarwal serve as directors at the Company.
- CIN/LLPIN
U24230DL2008PTC179122
- Company No.
179122
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Genetech Biotech Private Limited. offer?
Genetech Biotech Private Limited. offers a wide range of products and services, including Antibiotic Injection, Piperacillin Tazobactam Injection, Anticoagulant and Antiplatelet Drugs, Enoxaparin Injection, Injectable Products, Human Growth Hormone Injection, Antibacterial Drugs, Imipenem & Cilastatin Injection.
Who are the key members and board of directors at Genetech Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meena Aggarwal  | Director | 27-May-2018 | Current |
| Ashish Aggarwal | Director | 08-Nov-2012 | Current |
Financial Performance of Genetech Biotech.
Genetech Biotech Private Limited., for the financial year ended 2022, experienced significant growth in revenue, with a 11.51% increase. The company also saw a substantial improvement in profitability, with a 23.22% increase in profit. The company's net worth moved up by a moderate rise of 1.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genetech Biotech?
In 2019, Genetech Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Karur Vysya Bank Limited Creation Date: 15 Jan 2014 | ₹2.00 M | Open |
How Many Employees Work at Genetech Biotech?
Unlock and access historical data on people associated with Genetech Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genetech Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genetech Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
